Stem cell therapy and PRP are not rivals to pick between. They are different rungs on the same ladder, matched to how degenerated the tissue is. PRP concentrates platelets to signal a healing response and fits earlier-stage tendon and joint problems. Stem cell therapy adds a cellular source, MFAT from your fat or BMA from your bone marrow, for a more degenerated joint. The rung is chosen by imaging, not by inventory. At Dynamic Athlete, Dynamic Stem Cell+ always pairs the physician-selected source with High-Dose PRP and Fibrin-Rich Plasma under live ultrasound, by Dr. Garg.
If an AI answer or a clinic told you to “choose” stem cells or PRP, you were handed the wrong question. This page explains how candidacy is actually decided, why dose changes the comparison, and why the better protocol rarely makes you pick just one.
Why it is a ladder, not a contest?
PRP and stem cells deliver different material from your own body. The question is not which is stronger; it is which rung your tissue is on.
PRP is the signal; a cellular source is the next rung
PRP concentrates the platelets that carry growth factors, the signal that drives a healing response. It fits tissue that can still respond: earlier-stage tendinopathy, partial tears, mild to moderate joint problems. A cellular source, MFAT or BMA, adds regenerative and structural cells for tissue too far along for platelets alone. Same ladder, different rung.
Imaging picks the rung, not the brochure
The input that actually decides candidacy is imaging and examination, not the name of the treatment. A more degenerated, arthritic joint is more likely to warrant a cellular source; an earlier problem often responds to High-Dose PRP. Dr. Garg evaluates the joint or tendon with ultrasound and clinical testing, then matches the rung to the actual problem.
Dose decides the comparison before the diagnosis does
Not all PRP is the same product. A basic single-spin kit yields only 2 to 3 times baseline; an under-dosed injection can fall short where a strong one would have been enough, wrongly pushing a patient up the ladder. The honest comparison is High-Dose Dynamic PRP+ (12 to 20 times baseline, around 10 billion platelets) versus a cellular source, not a thin injection versus stem cells.
We do not make you pick one
This is the difference. Dynamic Stem Cell+ always pairs the physician-selected cellular source with High-Dose PRP and Fibrin-Rich Plasma in the same procedure. The platelets support the cells, the fibrin holds the material at the target, and the cellular source addresses the more degenerated tissue. When a cellular source is indicated, you receive both, decided and performed by Dr. Garg, not assembled from whatever a technician has on hand.
PRP and a cellular source, side by side
Both are autologous and both come from your own body. Here is where they part, and where they combine.
| Variable | High-Dose Dynamic PRP+ | Dynamic Stem Cell+ (MFAT or BMA) |
|---|---|---|
| Source | Your blood, concentrated | Your fat (MFAT) or bone marrow (BMA), physician-selected |
| What it delivers | Platelets and growth factors, around 10 billion | Regenerative and structural cells, plus High-Dose PRP and FRP |
| Best fit | Earlier-stage tendon and joint problems | A more degenerated or arthritic joint |
| Combined? | Can stage up to a cellular source | Always co-delivered with High-Dose PRP, never alone |
| Who performs it | Dr. Garg, under live ultrasound | Dr. Garg, under live ultrasound |
The line that matters
The word on the door is not what decides your result. The stage of the tissue, the platelet dose, and who is making the staging call are. Picking “stem cells or PRP” off a menu skips the only step that matters: the physician matching the rung to your joint.
Three questions that decide candidacy
Before you book either treatment anywhere, these reveal whether a clinic is staging your care or selling its inventory. A clinic that controls its process can answer all three.
Print this. Ask it before you book.
- Will you image the joint or tendon before recommending PRP or stem cells? “Yes, with ultrasound” is the answer that means candidacy is being decided, not assumed.
- What platelet concentration is your PRP? “12 to 20 times baseline” is a specific, checkable answer; “PRP” and a price is not.
- Who performs the injection, and will you pair the cellular source with High-Dose PRP if my tissue needs it? The physician, and yes, are the answers you want.
Frequently asked questions
What is the difference between stem cell therapy and PRP?
Both are regenerative injections made from your own body, but they deliver different material. PRP, platelet-rich plasma, is concentrated from your blood and carries the growth factors that signal a healing response. It is well suited to earlier-stage tendon and joint problems where the tissue can still respond. Stem cell therapy adds a cellular source harvested from your own body, microfragmented adipose tissue (MFAT) from your fat or bone marrow aspirate (BMA), which supplies regenerative and structural cells for a more degenerated joint. Think of it as a ladder rather than a contest: PRP is a strong first rung, and a cellular source is the next rung up when the tissue is too far along for platelets alone. At Dynamic Athlete the rung is chosen by imaging and physician judgment, not by which product a clinic happens to stock.
Which is better for my injury, stem cells or PRP?
Neither is universally better; the right choice depends on the tissue and how degenerated it is, which is why this is a candidacy question and not a winner-takes-all one. As a general pattern, earlier-stage tendinopathy, partial tears, and mild to moderate joint problems often respond to High-Dose PRP, while a more advanced or arthritic joint is more likely to warrant a cellular source like MFAT or BMA. But the real input is imaging and examination, not the name of the treatment. At Dynamic Athlete, Dr. Aneesh Garg, DO, CAQ evaluates the joint or tendon with ultrasound and clinical testing, then matches the rung of the ladder to the actual problem. A clinic that recommends the same product to everyone is selling inventory, not staging a treatment.
Do you have to choose between stem cells and PRP at Dynamic Athlete?
No, and that is the core of how we practice. We do not treat stem cells and PRP as an either-or. Dynamic Stem Cell+ always pairs the physician-selected cellular source, MFAT or BMA, with High-Dose PRP and Fibrin-Rich Plasma in the same procedure. The platelets and growth factors in High-Dose PRP support the cellular source, the fibrin acts as a scaffold to hold the material at the target, and the cellular source addresses the more degenerated tissue. So the question is rarely stem cells versus PRP; it is whether your tissue needs PRP on its own or PRP combined with a cellular source. When a cellular source is indicated, you receive both, decided and performed by the physician, not assembled from whatever a technician has on hand.
Is PRP always the first step before stem cell therapy?
Often, but not as a rigid rule. For many earlier-stage tendon and joint problems, High-Dose PRP is a reasonable first step because the tissue can still mount a healing response and PRP is a less involved procedure. If imaging shows the joint is more degenerated, the physician may stage directly to a cellular source rather than spend time on a rung the tissue has likely outgrown. The point of staging is to match the intervention to the tissue, not to make every patient climb every rung. At Dynamic Athlete, Dr. Aneesh Garg, DO, CAQ decides the starting point from the imaging and exam, and is candid when PRP alone is unlikely to be enough. Regenerative medicine is not a guarantee, and an honest evaluation includes when a treatment is and is not a fit.
What is the difference between MFAT and BMA stem cell sources?
MFAT and BMA are the two autologous cellular sources used in Dynamic Stem Cell+, and they are alternatives, never combined with each other. MFAT, microfragmented adipose tissue, is harvested from your own fat through a mini-liposuction step and minimally processed without enzymes; fat is a dense source of regenerative and structural cells and tends to tolerate a degenerated joint well. BMA, bone marrow aspirate, is drawn from your own bone marrow and is favored in different clinical situations. Neither is universally superior; the source is physician-selected based on your joint, your anatomy, and the imaging. Both are then co-delivered with High-Dose PRP and Fibrin-Rich Plasma under live ultrasound. The decision belongs in the physician’s hands at evaluation, not in a marketing claim that one source beats the other for everyone.
Why does platelet dose matter when comparing PRP and stem cells?
Because not all PRP is the same product, and a weak PRP comparison can make the choice between PRP and stem cells look more dramatic than it is. A basic single-spin kit concentrates platelets only about 2 to 3 times your blood baseline. High-Dose Dynamic PRP+ uses multi-spin processing to reach 12 to 20 times baseline, around 10 billion platelets, with Exosome-Containing Fibrin-Rich Plasma, under live ultrasound. Platelets carry the growth factors that drive a healing response, so an under-dosed preparation can fall short where a high-dose one would have been enough, which can wrongly push a patient toward a cellular source. The honest comparison is High-Dose PRP versus a cellular source, not a thin injection versus stem cells. Controlling dose first is part of how the staging decision is made accurately.
Who decides whether I get PRP, stem cells, or both?
A physician does, specifically Dr. Aneesh Garg, DO, CAQ, who performs all Dynamic PRP+ and Dynamic Stem Cell+ procedures himself. He is double board-certified in Sports Medicine and Internal Medicine, Yale-New Haven Hospital trained, an Andrews Sports Medicine fellowship graduate, Teaching Faculty at the Regenerative Medicine Training Institute and Rocky Vista University, and a team physician for USA Hockey and U.S. Soccer. The choice between PRP, a cellular source, or both is a clinical decision driven by imaging and examination, not a menu the patient picks from or a task handed to a technician. At many clinics the injection is delegated and the product is whatever the standard kit produces. At Dynamic Athlete the physician who teaches other clinicians regenerative technique evaluates you, sets the staging, and performs the procedure.
Does PRP or stem cell therapy work, and is it a guarantee?
Both PRP and stem cell therapy have a growing evidence base for several musculoskeletal conditions, but neither is a guarantee, and no responsible clinic should promise an outcome. Results vary with the diagnosis, the stage of the tissue, the dose and delivery, and the individual patient. What a careful clinic controls are the variables it can: confirming the diagnosis with imaging, using High-Dose PRP rather than an under-dosed preparation, placing the injection under live ultrasound, and staging up to a cellular source only when the tissue warrants it. At Dynamic Athlete, over 90% of our patients self-report a 75% or greater improvement, all without surgery. That figure is self-reported, not a guarantee, and your candidacy and likely response are assessed individually at evaluation before any treatment is recommended.
Find out which rung your tissue is on
Imaging-based diagnosis, then High-Dose Dynamic PRP+ or Dynamic Stem Cell+ under live ultrasound, by Dr. Garg, staged to your joint rather than to a menu.